# Praxis Precision Medicines, Inc.: overview

PRAX · Nasdaq · CIK 1689548 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/prax.md) · [Financials](/companies/prax/financials.md) · [Filings](/companies/prax/filings.md) · [Insiders](/companies/prax/insiders.md)

Latest reported revenue: [$0](/filings/0001689548-26-000029.md) for Q4 FY2025, three months to 2025-12-31, from the 10-K filed Feb 19, 2026 (XBRL us-gaap:Revenues, accession 0001689548-26-000029).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.3](/filings/0001689548-25-000111.md) | [7.5 d](/filings/0001689548-26-000029.md) | [0.0](/filings/0001689548-25-000058.md) | [0.0](/filings/0001689548-25-000092.md) | [0.0](/filings/0001689548-25-000111.md) | [0.0 d](/filings/0001689548-26-000029.md) | not reported | not reported |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(18819.5%)](/filings/0001689548-25-000111.md) | [(857.0%) d](/filings/0001689548-26-000029.md) | not reported | not reported | not reported | not reported | not reported | not reported |
| Net margin | % | [(17188.7%)](/filings/0001689548-25-000111.md) | [(786.3%) d](/filings/0001689548-25-000040.md) | not reported | not reported | not reported | not reported | not reported | not reported |
| Diluted EPS | $ per share | [(2.75)](/filings/0001689548-25-000111.md) | not reported | [(3.29)](/filings/0001689548-26-000047.md) | [(3.31)](/filings/0001689548-26-000083.md) | [(3.36)](/filings/0001689548-25-000111.md) | not reported | [(3.20)](/filings/0001689548-26-000047.md) | [(2.87)](/filings/0001689548-26-000083.md) |
| Free cash flow | $m | [(27.5) d](/filings/0001689548-25-000111.md) | [(56.1) d](/filings/0001689548-26-000029.md) | [(53.0)](/filings/0001689548-26-000047.md) | [(54.7) d](/filings/0001689548-26-000083.md) | [(65.1) d](/filings/0001689548-25-000111.md) | [(76.3) d](/filings/0001689548-26-000029.md) | [(86.2)](/filings/0001689548-26-000047.md) | [(77.8) d](/filings/0001689548-26-000083.md) |

- Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | [0.0](/filings/0001689548-24-000034.md) | [2.4](/filings/0001689548-26-000029.md) | [8.6](/filings/0001689548-26-000029.md) | [0.0](/filings/0001689548-26-000029.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | [(5164.4%)](/filings/0001689548-26-000029.md) | [(2340.3%)](/filings/0001689548-26-000029.md) | not reported |
| Net margin | % | not reported | not reported | [(5037.9%)](/filings/0001689548-26-000029.md) | [(2137.5%)](/filings/0001689548-26-000029.md) | not reported |
| Diluted EPS | $ per share | [(3.94)](/filings/0001689548-23-000044.md) | [(69.65)](/filings/0001689548-24-000034.md) | [(18.69)](/filings/0001689548-26-000029.md) | [(10.21)](/filings/0001689548-26-000029.md) | [(13.48)](/filings/0001689548-26-000029.md) |
| Free cash flow | $m | [(126)](/filings/0001689548-23-000044.md) | [(185)](/filings/0001689548-24-000034.md) | [(111)](/filings/0001689548-26-000029.md) | [(132)](/filings/0001689548-26-000029.md) | [(249)](/filings/0001689548-26-000029.md) |

- Revenue. XBRL Revenue: us-gaap:Revenues.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/prax/insiders.md)

| Date | Insider | Role | Transaction | Shares | Reported price | Value | Filing |
| --- | --- | --- | --- | ---: | ---: | ---: | --- |
| 2021-10-06 | [BSOF Parallel Master Fund L.P.](/insiders/1736665.md) | 10% owner | Sale (S) | 400,000 | $17.50 | $7.0m | [Form 4](/filings/0000899243-21-039704.md) |
| 2021-10-05 | [BSOF Parallel Master Fund L.P.](/insiders/1736665.md) | 10% owner | Sale (S) | 23,946 | $19.15 | $458.6k | [Form 4](/filings/0000899243-21-039264.md) |
| 2021-10-01 | [BSOF Parallel Master Fund L.P.](/insiders/1736665.md) | 10% owner | Sale (S) | 22,600 | $19.13 | $432.3k | [Form 4](/filings/0000899243-21-039264.md) |
| 2021-08-23 | [BSOF Parallel Master Fund L.P.](/insiders/1736665.md) | 10% owner | Sale (S) | 771 | $20.04 | $15.5k | [Form 4](/filings/0000899243-21-034149.md) |
| 2021-08-23 | [BSOF Parallel Master Fund L.P.](/insiders/1736665.md) | 10% owner | Sale (S) | 351,625 | $19.00 | $6.7m | [Form 4](/filings/0000899243-21-034149.md) |
| 2021-08-18 | [BSOF Parallel Master Fund L.P.](/insiders/1736665.md) | 10% owner | Sale (S) | 3,000 | $15.88 | $47.6k | [Form 4](/filings/0000899243-21-033841.md) |
| 2021-08-12 | [BSOF Parallel Master Fund L.P.](/insiders/1736665.md) | 10% owner | Sale (S) | 10,060 | $13.92 | $140.0k | [Form 4](/filings/0000899243-21-032969.md) |
| 2021-08-11 | [BSOF Parallel Master Fund L.P.](/insiders/1736665.md) | 10% owner | Sale (S) | 17,222 | $15.03 | $258.8k | [Form 4](/filings/0000899243-21-032969.md) |
| 2021-08-03 | [BSOF Parallel Master Fund L.P.](/insiders/1736665.md) | 10% owner | Sale (S) | 22,300 | $14.99 | $334.3k | [Form 4](/filings/0000899243-21-031824.md) |
| 2021-08-02 | [BSOF Parallel Master Fund L.P.](/insiders/1736665.md) | 10% owner | Sale (S) | 40,000 | $15.78 | $631.2k | [Form 4](/filings/0000899243-21-031302.md) |
| 2021-07-30 | [BSOF Parallel Master Fund L.P.](/insiders/1736665.md) | 10% owner | Sale (S) | 15,854 | $15.68 | $248.6k | [Form 4](/filings/0000899243-21-031302.md) |

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [Jupiter Topco LLC](/funds/2146052.md) | 2026-06-30 | $1.15bn | 3,421,374 |  | Not compared |
| [JANUS HENDERSON GROUP PLC](/funds/1274173.md) | 2026-03-31 | $1.11bn | 3,458,863 |  | Not compared |
| [FMR LLC](/funds/315066.md) | 2026-06-30 | $775.7m | 2,316,907 |  | Added +155,964 |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $767.5m | 2,292,585 |  | Reduced −32,344 |
| [PERCEPTIVE ADVISORS LLC](/funds/1224962.md) | 2026-06-30 | $681.6m | 2,035,986 |  | Unchanged |
| [BAKER BROS. ADVISORS LP](/funds/1263508.md) | 2026-06-30 | $587.0m | 1,753,198 |  | Unchanged |
| [Orbis Allan Gray Ltd](/funds/1663865.md) | 2026-06-30 | $512.2m | 1,529,788 |  | Reduced −942,692 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $447.0m | 1,335,185 |  | Added +578,437 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $413.6m | 1,235,299 |  | Added +13,355 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $343.7m | 1,026,443 |  | Added +142,205 |

## Recent filings

[All 504 filings](/companies/prax/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-08-06 | 08:32 ET | [10-Q](/filings/0001689548-26-000083.md) | Quarterly report, period 2026-06-30 | 0001689548-26-000083 |
| 2026-08-06 | 08:31 ET | [8-K](/filings/0001689548-26-000082.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001689548-26-000082 |
| 2026-07-07 | 17:05 ET | [8-K](/filings/0001689548-26-000072.md) | 8.01 Other events | 0001689548-26-000072 |
| 2026-07-02 | 16:30 ET | [8-K](/filings/0001104659-26-080356.md) | 4.01 Change of auditor; 9.01 Financial statements and exhibits | 0001104659-26-080356 |
| 2026-06-29 | 16:40 ET | [8-K](/filings/0001689548-26-000069.md) | 8.01 Other events | 0001689548-26-000069 |
| 2026-06-22 | 16:43 ET | [8-K](/filings/0001689548-26-000066.md) | 8.01 Other events | 0001689548-26-000066 |
| 2026-06-12 | 16:46 ET | [8-K](/filings/0001689548-26-000056.md) | 5.07 Shareholder vote results | 0001689548-26-000056 |
| 2026-06-01 | 16:28 ET | [8-K](/filings/0001689548-26-000053.md) | 8.01 Other events | 0001689548-26-000053 |
| 2026-05-07 | 16:16 ET | [8-K](/filings/0001689548-26-000049.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001689548-26-000049 |
| 2026-05-07 | 09:06 ET | [10-Q](/filings/0001689548-26-000047.md) | Quarterly report, period 2026-03-31 | 0001689548-26-000047 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001689548-26-000029.md), filed Feb 19, 2026.

## Forecast league

Not in this season’s league. [This season’s league](/leagues.md)

## About the filer

- CIK: 1689548
- Tickers: PRAX
- Exchange: Nasdaq
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:46 ET. No prices; not investment advice.